Evidence map›Paper›PMID 30332553›Full record

ArticleCancer biology & therapy2019

The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.

Zeran Yang, Guang Chen, Ye Cui, Guowen Xiao, Tianhao Su, Jianan Yu, Zhiyuan Zhang, Yanjing Han, Kailan Yang, Long Jin

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Observational
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Zeran Yanga Interventional radiology, Beijing Friendship Hospital , Capital Medical University , Beijing , China.
Guang Chena Interventional radiology, Beijing Friendship Hospital , Capital Medical University , Beijing , China.
Ye Cuib Department of Immunology, School of Basic Medical Sciences , Capital Medical University , Beijing , China.
Guowen Xiaoa Interventional radiology, Beijing Friendship Hospital , Capital Medical University , Beijing , China.
Tianhao Sua Interventional radiology, Beijing Friendship Hospital , Capital Medical University , Beijing , China.
Jianan Yua Interventional radiology, Beijing Friendship Hospital , Capital Medical University , Beijing , China.
Zhiyuan Zhanga Interventional radiology, Beijing Friendship Hospital , Capital Medical University , Beijing , China.
Yanjing Hana Interventional radiology, Beijing Friendship Hospital , Capital Medical University , Beijing , China.
Kailan Yanga Interventional radiology, Beijing Friendship Hospital , Capital Medical University , Beijing , China.
Long Jina Interventional radiology, Beijing Friendship Hospital , Capital Medical University , Beijing , China.
Capital Medical University · CNBeijing Friendship Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor (VEGFR2-TKI), apatinib has a certain anti-tumor effect for a variety of solid tumors. The present study evaluates its efficacy and safety in advanced hepatocellular carcinoma (HCC). In this study, 47 patients with advanced HCC were included. TACE monotherapy group included 22 patients that responded to TACE, while the group that received TACE and apatinib included 25 patients that progressed on TACE and were able to receive apatinib off label. Median overall survival (OS) was significantly improved in the apatinib plus TACE group compared with the TACE group. Similarly, apatinib in combination with TACE significantly prolonged median progression-free survival (PFS) compared with TACE monotherapy. Furthermore, there was a significant difference between combination therapy and monotherapy in both Barcelona clinic liver cancer (BCLC) B and BCLC C group. The combination therapy had a dramatic effect on OS and PFS for patients at both BCLC B and BCLC C level. The most common clinically adverse events of apatinib plus TACE group were fatigue, weight loss, hypertension, hand-foot syndrome and anorexia, which were manageable and tolerable. The efficacy analysis showed that there was no significant association of survival benefit with age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, hypertension and hand-foot syndrome. Patients with macrovascular invasion and extrahepatic invasion showed worse survival benefits. In conclusion, apatinib combined with TACE revealed certain survival benefits for HCC patients who experienced progression following TACE, which can provide a promising strategy for HCC treatment.

Indexed as

AgedAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticFemaleHumansLiver NeoplasmsMaleMiddle AgedProtein Kinase InhibitorsPyridinesRetrospective StudiesSurvival AnalysisAntineoplastic AgentsapatinibProtein Kinase InhibitorsPyridinesangiogenesisapatinibcombination therapy, vascular endothelial growth factor receptor-2hepatocellular carcinomatargeted therapytransarterial chemoembolization

Identifiers

PMID30332553
PMCPMC6370378
OpenAlexW2896972634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.